This is simply not true. NICE decides the amount that cannot be exceeded to extend a person's life beyond a year.
Last year Britain’s National Institute for Health and Clinical Excellence gave a preliminary recommendation that the National Health Service should not offer Sutent for advanced kidney cancer. The institute, generally known as NICE, is a government-financed but independently run organization set up to provide national guidance on promoting good health and treating illness. The decision on Sutent did not, at first glance, appear difficult. NICE had set a general limit of £30,000, or about $49,000, on the cost of extending life for a year.
http://www.nytimes.com/2009/07/19/magazine/19healthcare-t.html?pagewanted=1&_r=1
QALY isn't this big, bad, evil thing.
Search the New England Journal of Medicine (one of the medical journals with the best reputation and high impact rating) if you don't believe me.
They have some fantastic articles, evidence based articles, on the issues that the US is facing today.
They are also readily admitting the system is broken.
http://www.nejm.org/doi/full/10.1056/NEJMp1007168
Perspective
Legislating against Use of Cost-Effectiveness Information
In 1996, after 2 years of deliberation, the U.S. Panel on Cost-Effectiveness in Health and Medicine, composed of physicians, health economists, ethicists, and other health policy experts, recommended that cost-effectiveness analyses should use quality-adjusted life-years (QALYs) as a standard metric for identifying and assigning value to health outcomes.2
QALYs provide a convenient yardstick for measuring and comparing health effects of varied interventions across diverse diseases and conditions. They represent the effects of a health intervention in terms of the gains or losses in time spent in a series of “quality-weighted” health states. QALYs are used in cost-effectiveness analyses (termed “cost-utility analyses” when QALYs are included) to inform resource-allocation decisions: the cost-per-QALY ratios of different interventions are compared in order to determine the most efficient ways of furnishing health benefits. In contrast, other health outcomes are generally expressed in disease-specific terms, such as incidence of cardiovascular events, cancer progression, intensity of pain, or loss of function. Though useful for measuring the effects of particular treatments, these outcomes do not permit comparisons among diseases and conditions or between treatment and prevention.3
For the 'free-market' argument
http://www.nejm.org/doi/full/10.1056/NEJMp0911074
Table 1
TAnnual Cost of Expanded Insurance Coverage, According to the Amount of the Annual Premium. illustrates the most basic of these choices:
the more generous the insurance policy, the fewer the people who can be covered with a given budget. It shows the amount that it would cost to cover a certain number of people with policies of a certain level of generosity (as indicated by the per-person premium).
We chose these values on the basis of the distribution of premiums for individual coverage in the employer-sponsored health insurance market today, using data for employers with more than 50 workers from the 2008 Medical Expenditure Panel Survey (MEPS) conducted by the Agency for Healthcare Research and Quality.1 The median premium was $4,200, the premium at the 25th percentile was $3,500, and the premium at the 75th percentile was $5,100. This dispersion reflects many factors besides the generosity of policies, including geographic variation and enrollee characteristics (although basing the analysis on premiums paid by larger employers mitigates the effects of these characteristics). One could also think of the less generous policies as reflective of the typical premiums of a decade ago (for example, the 25th-percentile premium in 2008 was similar to the average premium in 2000, which was $3,500 after adjustment for inflation).
http://www.nejm.org/doi/full/10.1056/NEJMsb0911104
Comparative Effectiveness and Health Care Spending — Implications for Reform